Diabetes

Updated 27 February 2017

New drug approved for type 2 diabetes

Invokana (canaglifozin) has been approved by the US Food and Drug Administration to treat type 2 diabetes, which affects about 24 million Americans.

0

Invokana (canaglifozin) has been approved by the US Food and Drug Administration to treat type 2 diabetes, which affects about 24 million Americans.

The drug is among a new class of medications called sodium-glucose co-transporter 2 inhibitors. It works to block re-absorption of glucose by the kidneys, leading to more glucose being excreted by the body, the agency said in a news release.

The drug's safety and effectiveness were evaluated in nine clinical trials involving more than 10 200 people. The trials showed improvement in blood glucose levels and glucose control, the FDA said.

Invokana, which users should combine with proper diet and exercise, shouldn't be taken by people with type 1 diabetes, by those who have elevated ketones of the blood or urine, or by people with kidney impairment or end stage renal disease, the FDA said.

The most common side effects noted during clinical testing included vaginal yeast infection and urinary tract infection. The FDA said it's ordering five post-marketing studies to evaluate the drug's effects on children, the cardiovascular system, and the potential for increased risk of cancer, pancreatitis, severe hypersentivity reactions, adverse pregnancy outcomes, bone safety, and liver abnormalities.

The drug may lead to a sudden drop in blood pressure when a user stands up, the agency said.

Invokana is produced for Janssen Pharmaceuticals of Titusville, NJ.

More information

Visit Medline Plus to learn more about type 2 diabetes.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules